Department of Intervention, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Eur J Vasc Endovasc Surg. 2018 Apr;55(4):545-553. doi: 10.1016/j.ejvs.2017.12.016. Epub 2018 Feb 23.
The aim was to evaluate individualised treatment and long-term outcomes of endovascular treatment of Budd-Chiari syndrome (BCS) complicated by inferior vena cava (IVC) thrombosis.
Between April 2005 and December 2015, 108 consecutive patients with BCS complicated by IVC thrombosis underwent endovascular treatment. According to the type, size, extent, and degree of organisation of the thrombus, agitation thrombolysis (n = 7), agitation thrombolysis combined with retrieval stent filter (n = 5), pre-dilation (n = 32), retrieval stent filter (n = 56), or direct large balloon dilation (n = 8) was performed. Peri- and post-operative follow-up data were recorded.
The endovascular treatment was technically successful in 107 of the 108 patients (99.1%). The incidence of thrombosis related complications was 7.4% (8/108). Major and minor complications occurred in four patients. The mean follow-up duration was 61.7 ± 39.3 months (range 3-140 months). The cumulative 1, 2, 5, and 10 year primary patency rates were 91%, 88%, 79%, and 79%, respectively, and the cumulative 1, 2, 5, and 10 year secondary patency rates were 100%, 100%, 97%, and 97%, respectively. The cumulative 1, 5, and 10 year survival rates were 95%, 86%, and 81%, respectively. Serum albumin and total bilirubin values were independent predictors of survival.
For patients with BCS complicated by IVC thrombosis, an individualised endovascular treatment strategy based on the type, size, extent, and degree of organisation of the thrombus is associated with long-term patency of the IVC and favourable survival and complication rates.
评估布加综合征(BCS)合并下腔静脉(IVC)血栓形成患者的个体化治疗及长期疗效。
2005 年 4 月至 2015 年 12 月,连续 108 例 BCS 合并 IVC 血栓患者接受了血管内治疗。根据血栓的类型、大小、范围和组织化程度,采用搅拌溶栓(n=7)、搅拌溶栓联合回收支架滤器(n=5)、预扩张(n=32)、回收支架滤器(n=56)或直接大球囊扩张(n=8)。记录围手术期及随访资料。
108 例患者中,107 例(99.1%)血管内治疗技术成功。血栓相关并发症发生率为 7.4%(8/108)。4 例患者出现主要和次要并发症。平均随访时间为 61.7±39.3 个月(3-140 个月)。累积 1、2、5 和 10 年的初始通畅率分别为 91%、88%、79%和 79%,累积 1、2、5 和 10 年的继发通畅率分别为 100%、100%、97%和 97%。累积 1、5 和 10 年的生存率分别为 95%、86%和 81%。血清白蛋白和总胆红素值是生存的独立预测因素。
对于 BCS 合并 IVC 血栓形成的患者,根据血栓的类型、大小、范围和组织化程度制定个体化的血管内治疗策略,与 IVC 的长期通畅率以及良好的生存率和并发症发生率相关。